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decreases expression of contractile proteins and
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cells
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Konstantinos Gourgoulianis4 and Apostolia Hatziefthimiou1*Abstract
Background: Chronic airway diseases, like asthma or COPD, are characterized by excessive acetylcholine release
and airway remodeling. The aim of this study was to investigate the long-term effect of muscarinic agonists on the
phenotype and proliferation of rabbit tracheal airway smooth muscle cells (ASMCs).
Methods: ASMCs were serum starved before treatment with muscarinic agonists. Cell phenotype was studied by
optical microscopy and indirect immunofluorescence, using smooth muscle α-actin, desmin and SM-Myosin Heavy
Chain (SM-MHC) antibodies. [N-methyl-3H]scopolamine binding studies were performed in order to assess M3
muscarinic receptor expression on isolated cell membranes. Contractility studies were performed on isolated ASMCs
treated with muscarinic agonists. Proliferation was estimated using methyl-[3H]thymidine incorporation, MTT or cell
counting methods. Involvement of PI3K and MAPK signalling pathways was studied by cell incubation with the
pathway inhibitors LY294002 and PD98059 respectively.
Results: Prolonged culture of ASMCs with acetylcholine, carbachol or FBS, reduced the expression of α-actin, desmin
and SM-MHC compared to cells cultured in serum free medium. Treatment of ASMCs with muscarinic agonists for
3-15 days decreased muscarinic receptor expression and their responsiveness to muscarinic stimulation. Acetylcholine
and carbachol induced DNA synthesis and increased cell number, of ASMCs that had acquired a contractile phenotype
by 7 day serum starvation. This effect was mediated via a PI3K and MAPK dependent mechanism.
Conclusions: Prolonged exposure of rabbit ASMCs to muscarinic agonists decreases the expression of smooth muscle
specific marker proteins, down-regulates muscarinic receptors and decreases ASMC contractile responsiveness.
Muscarinic agonists are mitogenic, via the PI3K and MAPK signalling pathways.
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The airway smooth muscle is implicated in the patho-
logical process of chronic airway diseases, such as
asthma and chronic obstructive pulmonary disease [1].
These diseases exhibit common features like increased
parasympathetic activity and acetylcholine release [2], or* Correspondence: axatzi@med.uth.gr
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reproduction in any medium, provided the orairway remodeling [3]. Airway remodeling comprises
changes in the composition, quantity and organization
of airway wall components as consequence of chronic
injury and repair of the airway epithelial–mesenchymal
trophic unit [1,4]. The increased thickness of the smooth
muscle layer could enhance shortening, leading to in-
creased airway narrowing and airflow obstruction [1].
ASMC cultures are a mixed population of cells exhibiting
variability between contractile and synthetic-proliferative
phenotypes [5]. The distinction between ASMC phenotypes
is based on the different expression of proteins implicatedtral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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tein synthesis. Synthetic-proliferative ASMCs appear to
proliferate, while the features of contractile ASMCs are
similar to those of the cells normally present in intact
airway tissue [4]. Different stimuli drive the transition
between the different ASMC phenotypes. Although the
mechanism involved is not yet well understood, evi-
dence supports the hypothesis that the p42/p44 MAPK
pathway is involved in the shift of ASMCs toward a less
contractile phenotype [6-9]. On the other hand, serum
deprivation increases the percentage of cells that exhibit
the “contractile phenotype” in ASMC culture [10]. The
shift of ASMCs from synthetic-proliferative to contract-
ile phenotypes is attended by a decrease in M2 and a
parallel increase in M3 expression [11].
ASMCs express abundant Gi coupled muscarinic M2
and Gq coupled M3 muscarinic receptors [12,13], stimu-
lation of which leads to the activation of the MAPK and
the PI3K signalling pathways [14]. M2 and/or M3-receptor
stimulation by muscarinic agonists could affect ASMC
proliferation, but until now muscarinic receptor agonists
have been reported to be mitogenic for ASMCs mainly in
combination with growth factors [11,15], acting through
M3 muscarinic receptors [11]. On the other hand, the
effect of muscarinic agonists on ASMC phenotype and in
consequence their ability to proliferate has not been thus
far fully addressed. In the present study we investigate the
effect of prolonged cell incubation with muscarinic ago-
nists, acetylcholine or carbachol, on phenotype shifting
and cell contractility of ASMC obtained from rabbit tra-
chea. We also studied the mitogenic effect of muscarinic




Adult rabbits were maintained in individual cages in a
controlled environment and were provided with food
and water before use for the study. Animals were treated
in compliance with ethical and institutional guidelines.
All protocols were approved by the Ethics Committee of
the Department of Medicine, School of Health Sciences
of University of Thessaly. Rabbits were euthanised by
an overdose of intravenously administrated Pentothal
(Abbott, Abbott Park, IL, USA).
ASMC isolation and culture
The isolation of ASMC from adult rabbit trachea was
done as previously described [16]. Briefly, tracheal smooth
muscle was epithelium denuded, dissected from cartilage
and washed in low Ca2+ Krebs solution (139 mM NaCl,
5.4 mM KCl, 1.47 mM MgSO4, 11 mM glucose, 1.47 mM
KH2PO4, 2.8 mM Na2HPO4, 1.4 mM NaHCO3, 0.2 mM
CaCl2). Tracheal smooth muscle was digested in 2 ml oflow Ca2+ Krebs solution containing 0.25% bovine serum
albumin (BSA), 2 mg/ml collagenase I and 10 U/ml elas-
tase IV, for 30 min at 37°C with vigorous shaking. Then
it was washed in low Ca2+ Krebs solution, centrifuged
(1000 rpm for 10 min) and incubated for 45 min in low
Ca2+ Krebs solution containing 0.25% BSA, 1 mg/ml colla-
genase I and 20 U/ml elastase IV. Dispersed ASMCs were
washed and centrifuged (1000 rpm for 10 min) twice in
Dulbecco’s modified Eagle’s medium/Ham/F12 (DMEM/
F12) containing 10% fetal bovine serum (FBS), 100 U/ml
penicillin and 100 g/ml streptomycin. The isolated ASMC
were placed in culture flasks and grown at 37°C in a humi-
fied incubator under 5% CO2.
Study design
Isolated tracheal ASMCs were serum starved by incuba-
tion in Dulbecco’s modified Eagle’s medium/Ham/F12
(DMEM/F12) containing 100 U/ml penicillin and 100 g/
ml streptomycin, as indicated, and treated with the mus-
carinic agonists, acetylcholine (ACh; 10-7 M-10-3 M), or
carbachol (CCh; 10-9 M-10-5 M). The effect of the mus-
carinic agonists on the ASMC phenotype was studied
using optical microscopy, as well as indirect immunofluor-
escence, and Western blot analysis with anti-smooth
muscle α-actin mouse monoclonal antibody, anti-myosin
(smooth) clone HSM-V mouse monoclonal antibody and
anti-desmin rabbit polyclonal antibody. The density of
muscarinic receptors on ASMCs was studied with [N-me-
thyl-3H]scopolamine binding on isolated cell membranes
and the effect of acetylcholine and/or carbachol on the
contractile ability of individual ASMCs in culture was es-
timated by counting the cell area before and after mus-
carinic agonist treatment in the presence or absence of
atropine.
Cell proliferation was estimated using the methyl-[3H]
thymidine incorporation, the MTT-Cell Titer 96® AQue-
ous One Solution Assay (Promega) and Trypan blue cell
counting methods. In the MTT cell proliferation assay,
the optical density (OD) of cells incubated in serum-free
medium (24 h) was used as control (set at 100%). Results
are presented as percentage of OD of the control cells,
while the DNA synthesis is presented as cpm of radio-
active material incorporated in ASMCs. The possible
involvement of PI3K and MAPK signalling pathways
was studied using the pathways inhibitors LY294002
and PD98059 respectively.
Cell culture treatment
ASMCs were trypsinised, counted and seeded into ap-
propriate cell culture plates. They were allowed to ad-
here overnight, washed twice with phosphate buffered
saline (1XPBS) and pre-incubated in FBS-free DMEM/
F12 medium, containing 100U/ml penicillin and 100 μg/ml
streptomycin. ASMCs were incubated in serum free
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containing medium or serum free medium in the presence
or absence of increasing concentrations of the mus-
carinic agonists; acetylcholine (10-7 M-10-3 M) and car-
bachol (10-9 M-10-5 M) as indicated. Specifically, cells
were incubated with ACh (10-7 M) or CCh (10-9 M) in
morphology observation and thymidine incorporation
experiments, with ACh (10-5 M) or CCh (3 × 10-7 M) in
contractile phenotype marker protein expression, M3
muscarinic receptor expression and cell proliferation
experiments and with ACh (10-3 M) or CCh (10-5 M) in
responsiveness experiments. The culture medium was
replaced every 3 days, during the incubation periods.
For the study of the possible involvement of PI3K and/
or MAPK signalling pathways, LY294002 (20 μΜ) and
PD98059 (100 μΜ) inhibitors were added in cell culture
medium 15 or 60 min prior to the addition of the mus-
carinic agonists, respectively.
Cell morphology
Cell morphology was observed with a reverse microscope
Nikon Diaphot 300 (Nikon Inc., Melville, NY, USA).
Indirect immunofluorescence
Cells were plated onto glass slides, which were resided in
culture plates and treated as indicated above. After the
treatment, cells were fixed with PBS-3% formaldehyde
and permeabilized with PBS-1% Triton X-100, blocked in
PBS-0.1% Tween 20- 3% BSA and incubated with anti-
smooth muscle α-actin mouse monoclonal antibody
(1:1000, Sigma), anti-myosin (smooth) clone HSM-V
mouse monoclonal antibody (1:1000, Sigma) and anti-
desmin rabbit polyclonal antibody (1:1000, Sigma), followed
by incubation with an anti-mouse IgG or anti-rabbit
IgG antibodies conjugated with CY3. Finally, coverslips
were mounted on Vectrashield solution containing DAPI
for DNA staining and the percentage of the cells that
expressed α-actin, SM-MHC (Smooth muscle-Myosin
Heavy Chain) and desmin proteins was estimated.
Western blot analysis
Cells were lysed in 20 mM Tris-Cl pH 8.0, 150 mM NaCl,
1% Triton X-100, 1 mM dithiothreitol, and 100 mg/mL-1
phenylmethylsulphonyl fluoride. Total cell extracts were
cleared by centrifugation (10000 g for 20 min at 4°C).
40 mg of protein were analysed in 10% sodium dodecyl
sulphate–polyacrylamide electrophoresis gel and trans-
ferred to a nitrocellulose membrane. Western blot ana-
lysis was performed using anti- smooth muscle β-actin
mouse monoclonal antibody (1:5000, Cell Signalling),
anti-smooth muscle α-actin mouse monoclonal antibody
(1:1000, Sigma), anti- myosin (smooth) clone HSM-V
mouse monoclonal antibody (1:1000, Sigma) and anti-
desmin rabbit polyclonal antibody (1:1000, Sigma).Membranes were then incubated with horseradish per-
oxidase conjugated anti-rabbit IgG (1:3000, Cell Sig-
nalling) or anti-mouse IgG (1:3000, Cell Signalling),
and signals visualised by enhanced chemolumines-
cence (ECL).[N-methyl-3H]scopolamine binding studies
The binding of [N-methyl-3H]scopolamine ([3H]NMS)
was done as previously described [17]. Briefly, ASMCs
were serum deprived for 24 h and then incubated for
3, 7 or 15 days with 10% FBS, ACh (10-5 M) or CCh
(3 × 10-7 M). Control cells were incubated in serum free
medium. Cells were lysed by scraping in buffer (25 mM
Tris-HCl, 2.5 mM CaCl2, 1 mM PMSF, 1 mM Pefabloc
and 10 μg/ml aprotinin). Cell extracts were homoge-
nized with 5 strokes in a Heidolph Silent Crusher S
(Heidolph Instruments GmbH & Co. KG, Germany) and
the homogenate was centrifuged at 10000 g for 5 min at
4°C. The supernatant was diluted up to 11 ml in assay
buffer (10 mM HEPES, 100 mM NaCl, 10 mM MgCl2)
and centrifuged at 150000 g for 30 min at 4°C. The pel-
let was then resuspended in assay buffer and subjected
to sonication for 5 sec. 30 μg of protein was added in
the reaction, along with 5 nM of [3H]NMS. Nonspecific
binding was estimated by the presence of 100 μM atro-
pine. After 80 min of incubation in order to allow radi-
oligand binding only to M3 receptors [17], the samples
were filtered through GF/B filters (Millipore) using a
Millipore vacuum filtration system (EMD Millipore Cor-
poration, Billerica, MA, USA). Before radiation counting
in a Wallac β-counter, filters were dried overnight and
incubated in Ultimate gold XR (Perkin Elmer) scintilla-
tion fluid for 1 h at RT.Contractility studies
ASMCs were grown to confluence in culture plates and
incubated 3-15 days in serum-free medium, or medium
containing 10% FBS, acetylcholine (10-5 M), carbachol
(3 × 10-7 M). The cells were washed twice with phos-
phate buffered saline (1xPBS), and then incubated for
5 min with trypsin-EDTA solution, in order to detach
myocytes from the substrata. The detached cells were
incubated with acetylcholine (10-3 M) or carbachol
(10-5 M) for 5 min. Photographs were taken before and
after cell treatment, in a phase-contrast microscopy
Nikon Diaphot 300 (Nikon Inc., Melville, NY, USA)
with Leica DFC480 Camera (Leica Microsystems, Wetzlar,
Germany). The ratio of total cell area before and after
treatment was measured using the Image J programme.
To confirm that contractile shortening responses were the
direct result of ACh or CCh stimulation, atropine (10-6 M)
was added in control experiments before ACh or CCh
exposure.
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Proliferation of cultured ASMCs was estimated using
(A) the methyl-[3H]thymidine incorporation method,
(B) the MTT-Cell Titer 96® AQueous One Solution
Assay (Promega) method and (C) the Trypan blue
method.
(A) DNA synthesis in airway smooth muscle cells was
estimated by measuring methyl-[3H]thymidine incorpor-
ation. Methyl-[3H]thymidine was added in the culture
medium the last 18 h of incubation. The counts per mi-
nute (cpm) of the radioactive DNA were counted using
a Wallac scintillation counter. Cells incubated in serum
free medium were used as negative control in each ex-
periment. The proliferating capability of cells was evalu-
ated by positive controls, which were cells incubated in
10% FBS.
(B) The number of airway smooth muscle cells was es-
timated using the Cell Titer 96® AQueous One Solution
Assay (Promega) method as previously described [18].
The absorbance of the MTT formazan reduction prod-
uct was measured at 490 nm with a reference at 630 nm
in an ELISA plate reader. The measured optical density
(OD) is reminiscent of the cell number in the well, since
there is a linear response between the measured OD and
cell number (data not shown).
(C) Cell number was estimated by direct cell counting,
using the Trypan blue method. Trypan blue dye was
added to ASMCs detached and suspended in 1ΧPBS so-
lution and live cells that did not absorb the dye were
counted using a Neubauer slide.Data analysis
In ASMCs contractility studies each point represents
the mean value of 5 cells, while in [3H]NMS binding
and cell proliferation experiments each point was per-
formed in triplicate. In immunofluorescence experi-
ments the percentage of cells expressing the contractile
proteins was estimated by counting the cells that were
fluorescent, as well as the total cell number as indicated
by DAPI staining. Image analysis of the images obtained
from the Western blotting and the contractility studies
was conducted with the use of MacBiotronics Image J
programme for Light Microscopy (National Institutes of
Health, Bethesda, MD, USA) and results were expressed
as intensity values or as percentage of the initial cell
area, respectively.
All data are expressed as means ± SEM and N refers
to the number of independent experiments. Differences
between means were analysed by Unpaired t-test with
statistically significant differences between groups being
determined by Mann-Whitney test. A comparison was
considered significant when P < 0.05. The statistical ana-
lysis was performed using Graph Prism.Results
The effect of muscarinic agonists, acetylcholine (ACh) or
carbachol (CCh), on ASMC phenotype
Rabbit tracheal ASMCs were incubated in serum free
medium for 24 h in order to get synchronised. ASMCs
were then incubated in serum free medium, medium
containing ACh (10-7 M), CCh (10-9 M) or 10% FBS for
up to 30 days and their morphology was examined by
phase contrast microscopy (Figure 1). ASMCs grown in
the absence of FBS appeared elongated, while cells incu-
bated in FBS-containing medium appeared flat. ASMCs
incubated with ACh or CCh comprised a mixed popula-
tion; part of which appeared flat, phenotypically similar to
ASMCs incubated in the presence of FBS (indicated by ar-
rows), while the rest maintained the elongated phenotype
of cells incubated in serum free medium. The number of
cells undergoing this morphological switch increased as
time of incubation with ACh or CCh increased (data not
shown).
For further evaluation of the effect of muscarinic agonists
on ASMCs morphology, 24 h-serum deprived ASMCs
were cultured in serum-free medium or medium contain-
ing 10% FBS, ACh (10-5 M) or CCh (3 × 10-7 M) for up to
15 days and the expression of smooth muscle specific
markers was studied. The mean or individual cell expres-
sion of smooth muscle specific proteins α-actin, desmin
or SM-MHC, was analyzed by western blot analysis or
indirect immunofluorescence, respectively. Incubation of
ASMCs in the presence of ACh or CCh resulted in a de-
crease of individual cell and mean expression of α-actin
(Figure 2), desmin (Figure 3) and SM-MHC (Figure 4),
compared to ASMCs incubated in serum free medium.
Moreover, this reduction in smooth muscle specific protein
expression was similar to that of FBS.
The effect of muscarinic agonists on muscarinic receptor
expression
In order to determine the presence of M3 receptors,
ASMCs were subjected to serum starvation for 24 h, and
then incubated in serum free medium (control) or
medium containing ACh (10-5 M), CCh (3 × 10-7 M) or
10% FBS for 3-15 days. Cell membrane fractions were iso-
lated, equal amounts of protein (30 μg) were incubated
with [3H]NMS (5 nM) for 80 min at room temperature in
the presence or absence of 100 μM atropine and specific
binding of [3H]NMS was calculated. Binding of [3H]NMS
to ASMC membranes was similar in all samples after 3
days, but was significantly lower compared to respective
control (P < 0.05) after 7 or 15 days of incubation in
ACh, CCh or FBS (Figure 5). Interestingly, prolonged
incubation in serum free medium, increased the binding
of [3H]NMS to membranes of control cells incubated
to 7 or 15 days compared to cells incubated for 3 days
in the absence of FBS.
Figure 2 Muscarinic agonists reduce the expression of smooth muscle α-actin in ASMCs. A. Western blot analysis with anti-α-actin and
anti-β-actin antibodies in total protein extracts from ASMCs incubated for 15 days in serum free medium (control) or in medium containing 10%
FBS, ACh (10-5 M) or CCh (3 × 10-7 M). B. Quantification of α-actin expression normalized to the expression of β-actin presented in A. C. Specific
α-actin expression by indirect immunofluorescence in ASMCs incubated for 15 days in serum free medium (control) or in medium containing
10% FBS, ACh (10-5 M) or CCh (3 × 10-7 M). Nuclei were stained with DAPI (lower panel). D. Counting of the percentage of rabbit tracheal smooth
muscle cells which express α-actin in C. Ν = 4 independent experiments. *P < 0.05 compared with control.
Figure 1 Long-term treatment with muscarinic agonist affects ASMC morphology. ASMCs were incubated for 30 days in serum free
medium (control) or medium containing 10% FBS, ACh (10-7 M) or CCh (10-9 M) and their morphology was examined by optical microscopy
(magnification × 20). The arrows are pointing at cells exhibiting synthetic phenotype.
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Figure 3 Muscarinic agonists reduce the expression of contractile phenotype marker desmin in ASMCs. A. Western blot analysis with
anti-desmin and anti-β-actin antibodies in total protein extracts from ASMCs incubated for 15 days in serum free medium (control) or in medium
containing 10% FBS, ACh (10-5 M) or CCh (3 × 10-7 M). B. Quantification of desmin expression normalized to the expression of β-actin presented
in A. C. Specific desmin expression by indirect immunofluorescence in ASMCs incubated for 15 days in serum free medium (control) or in
medium containing 10% FBS, ACh (10-5 M) or CCh (3 × 10-7 M). Nuclei were stained with DAPI (lower panel). D. Counting of the percentage of
rabbit tracheal smooth muscle cells which express desmin in C. Ν = 4 independent experiments. *P < 0.05 compared with control.
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We then measured the effect of prolonged incubation
with ACh or CCh on ASMCs contractility. Therefore,
ASMCs were grown to confluence in culture plates, serum
starved for 24 h and maintained for 3-15 days in serum-
free medium, or medium containing 10% FBS, ACh (10-5
M) or CCh (3 × 10-7 M). Then, the medium was removed,
PBS was added, ASMCs were detached from the plate, the
cell’s area was measured, cell contraction was provoked by
the addition of ACh (10-3 M) or CCh (10-5 M) for 5 min
and the cell’s area was measured again. Cell responsiveness
to ACh or CCh was estimated as percentage of the single
cell area measured before and after the addition of ACh
or CCh. In control cells at day 0, the addition of ACh or
CCh in the culture medium for 5 min decreased the cell
surface to 78.3 ± 4.3% or 88.4 ± 3% of initial area re-
spectively (Figure 6A). This effect of muscarinic ago-
nists was specific, as it was abolished in the presence of
atropine (10-6 M) (Figure 6A). ASMCs cultured in 10%
FBS showed a decreased responsiveness to ACh or CCh
(P < 0.05; Figure 6B-D) compared to serum starved cells
(control). Similarly, the responsiveness to both mus-
carinic agonists of cells cultured for 3 to 15 days inmedium containing 10-5 M ACh or 3×10-7 M CCh was
significantly reduced compared to control cells (P < 0.05;
Figure 6B-D).
The effect of muscarinic agonists on ASMC proliferation
ASMCs were serum starved for 24 h and then treated
with ACh or CCh in order to study the effect of the mus-
carinic agonists on ASMC proliferation by measuring
methyl-[3H]thymidine incorporation and ASMC number.
Both ACh (10-7 M) or CCh (10-9 M) caused a significant
increase of methyl-[3H]thymidine incorporation after 48 h
of incubation (P < 0.01, Figure 7). We next studied the
involvement of the PI3K and MAPK signalling pathways
in the induction of methyl-[3H]thymidine incorporation
by ACh or CCh in rabbit tracheal ASMCs. The increase
in methyl-[3H]thymidine incorporation caused by ACh,
was lower in the presence of the PI3K and MAPK path-
way inhibitors LY294002 and PD98059, respectively,
although the effect of PD98059 was not statistically sig-
nificant (Figure 7, middle group of bars). In contrast,
only PD98059 but not LY294002 affected the increase
in methyl-[3H]thymidine incorporation caused by CCh
(Figure 7, right group of bars). Neither the PI3K inhibitor,
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Figure 4 Muscarinic agonists reduce the expression of contractile phenotype marker smooth muscle myosin heavy chain (SM-MHC) in
ASMCs. A. Western blot analysis with anti-SM-MHC and anti-β-actin antibodies in total protein extracts from ASMCs incubated for 15 days in
serum free medium (control) or in medium containing 10% FBS, ACh (10-5 M) or CCh (3 × 10-7 M). B. Quantification of SM-MHC expression
normalized to the expression of β-actin presented in A. C. Specific SM-MHC expression by indirect immunofluorescence in ASMCs incubated for
15 days in serum free medium (control) or in medium containing 10% FBS, ACh (10-5 M) or CCh (3 × 10-7 M). Nuclei were stained with DAPI
(lower panel). D. Counting of the percentage of rabbit tracheal smooth muscle cells which express SM-MHC in C. Ν = 4 independent experiments.
*P < 0.05 compared with control.
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PD98059 (100 μΜ) had an effect on methyl-[3H]thymidine
incorporation in control cells, while they both decreased
significantly methyl-[3H]thymidine incorporation, induced
by the incubation of cells with 10% FBS for 48 h (data not
shown).
Incubation of ASMCs with ACh (10-5 M) or CCh (3 ×
10-7 M) under the same conditions (24 h serum starvation,
incubation with ACh or CCh for 72 h) did not change
rabbit tracheal ASMC number, as estimated using CellFigure 5 The effect of muscarinic agonists ACh and CCh on N-methyl
were incubated for 3-15 days in serum free medium (control) or medium c
was calculated using 5 nM of [3H]NMS in triplicate for each condition. #P < 0.0
the respective control.Titer 96 AQueous One Solution Assay (Promega) method
(data not shown). Previous reports have shown that serum
deprivation increases the percentage of cells that express
the “contractile phenotype” in ASMC culture [19] and the
expression of M3 muscarinic receptors [11]. Moreover, as
shown in Figure 5, incubation in serum free medium for 7
days increases binding of [3H]NMS to ASMC membranes.
Thus it is possible that the lack of cell number increase by
ACh or CCh, is caused by the absence of a potent number
of M3 muscarinic receptors on the cytoplasmic membrane-[3H]scopolamine ([3H]NMS) specific binding. Rabbit tracheal ASMCs
ontaining 10% FBS, ACh (10-5 M) or CCh (3 × 10-7 M). Specific binding
5 compared with cells serum starved for 3 days. *P < 0.05 compared with
Figure 6 The effect of 3-15 days of incubation with muscarinic agonists ACh and CCh on ASMC responsiveness. A. Cell responsiveness to
ACh (10-3 M) or CCh (10-5 M) in the presence or absence of atropine (10-6 M). B-D. ACh (10-3 M) and CCh (10-5 M)-induced contractions of rabbit
tracheal smooth muscle cells cultured as indicated in serum free medium (control), medium containing 10% FBS, ACh (10-5 M) or CCh (3 × 10-7 M) for
3 (B), 7 (C) or 15 (D) days. Cell responsiveness to ACh or CCh was estimated as a percentage of the area of cell measured 5 min after the addition of
ACh or CCh in cell medium to the initial area before the addition of muscarinic agonist. *P < 0.05 and **P < 0.01 compared with the respective control.
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medium, before the addition of the muscarinic agonists.
We, therefore, tested the effect of ACh or CCh on the
proliferation of rabbit tracheal ASMCs that have been
subjected to prolonged serum starvation and performed
a time course experiment. Rabbit tracheal ASMCs were
incubated for 7 days in serum free medium and then
ACh (10-5 M) or CCh (3 × 10-7 M) was added to the cul-
ture medium for 1 to 15 days. Cell number was estimated
with MTT-Cell Titer 96® AQueous One Solution Assay
(Figure 8A) and Trypan blue method (Figure 8B). Both
methological approaches revealed that ASMC number
increased significantly compared to control after 1 day of
incubation with ACh and CCh, while no further increase
was observed after up to 15 days cell incubation with the
muscarinic agonists (Figure 8). The mitogenic effect of
ACh and CCh on rabbit tracheal ASMC number was
significantly (P < 0.05) reduced by the MAPK inhibitor
PD98059 (100 μΜ) (Figure 9A) as well as by the PI3K
pathways inhibitor LY294002 (20 μΜ) (Figure 9B).
Discussion
In airway smooth muscle, muscarinic agonists may acti-
vate signalling pathways such as the Rho kinase, PI3K orMAPK pathways [2]. Since the MAPK pathway is involved
in modulation of ASMCs toward a less contractile pheno-
type [6,7,10], we hypothesized that muscarinic agonists
could affect ASMC phenotype. Indeed, we found that
rabbit tracheal ASMCs subjected to prolonged (30
days) incubation with ACh or CCh switched to a prolif-
erative phenotype, i.e. cells appeared flat, similar to that
observed in ASMCs cultured in the presence of 10%
FBS. Accordingly, indirect immunofluoresence, as well
as western blot analysis experiments demonstrated that
this “induction” of a proliferative phenotype was accom-
panied by a significant decrease in the expression of the
contractile phenotype markers α-actin, SM-MHC and
desmin. To our knowledge, this is the first study report-
ing that muscarinic agonists induce the shift of ASMCs
toward a proliferative phenotype. Our results are in
agreement with a previous study by Gosens et al. [20]
who showed that prolonged treatment with the muscar-
inic agonist methacholine of bovine tracheal smooth
muscle strips in organ-cultures diminished the expres-
sion of myosin and actin.
Furthermore, there are studies indicating that the
switch of ASMC phenotype from proliferative to con-




















Figure 7 Muscarinic agonists increase the methyl-[3H]thymidine incorporation in ASMCs. Involvement of PI3K and MAPK signalling
pathways. Rabbit tracheal ASMCs were serum starved for 24 h and then incubated with ACh (10-7 M) or CCh (10-9 M) alone and in the
presence of the PI3K pathway inhibitor LY294002 (20 μΜ) or the MAPK pathway inhibitor PD98059 (100 μΜ). Methyl-[3H]thymidine incorporation was
measured after 48 h of incubation with the muscarinic agonist. **P < 0.01 compared with control. #P < 0.05 compared with the effect of muscarinic
agonist alone on methyl-[3H]thymidine incorporation.
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cordingly, our results demonstrate that the ACh or CCh
induced shift of the cell phenotype towards a prolifera-
tive one, was followed by a decrease of the M3 receptors
density, as shown by decreased [3H]NMS binding in
cells incubated with ACh or CCh for 7-15 days. Evidence
suggests that agonists may induce phosphorylation and
internalization of muscarinic receptors [21]. In our study,
the down regulation of M3 receptors of ASMCs was ac-
companied by decreased responsiveness of isolated cells,
incubated for 3-15 days with muscarinic agonists, to ACh
or CCh, due probably also by the decrease of smooth
muscle protein expression. These results are in agreement
with results obtained from contractility studies demon-
strated that long-term methacholine pretreatment of
bovine tracheal smooth muscle strips decreased max-
imal contraction and sensitivity to methacholine [20]. In
vivo studies revealed increased cholinergic tone in asthma
[22] and clinical studies showed that the addition of anti-
cholinergic drugs to the corticosteroid or long-acting β₂-
agonist treatment is beneficial for asthmatic patients
[23,24]. On the other hand in vitro studies performed
with bronchial smooth muscle from asthmatic patients
showed that the altered airway responsiveness seen in
asthmatic patients is not reflected in airway smoothmuscle sensitivity in vitro and that the sensitivity to carba-
chol was significantly reduced in tissue from asthmatic pa-
tients [25,26].
Even though a more proliferative phenotype was in-
duced by muscarinic agonists, this phenotype is not ne-
cessarily associated to increased proliferative capacity,
since each phenotype has different expression of pro-
teins, as well as receptors that affect the activation of
signalling pathways that are involved in the proliferation
process. We studied the proliferative effect of muscarinic
agonists ACh and CCh on ASMCs that were serum
starved for 24 h or 7 days. According to our results and
previous studies [5], 24 h serum starved cells express
mainly the proliferative ASMC phenotype while 7 days
serum starved cells express an increased percentage of
ASMCs with contractile phenotype. We found that
ACh and CCh increased [3H]thymidine incorporation
in rabbit tracheal ASMCs, serum starved for 24 h be-
fore muscarinic agonists addition (Figure 7), but did
not affect cell number (data not shown). On the other
hand when cells grew in serum free medium for 7 days
prior to the addition of ACh and CCh, both muscarinic
agonists significantly increased cell number (Figures 8
and 9). This effect was transient since no further in-
crease was observed after 24 h (2-15 days incubation
Figure 8 Muscarinic agonists increase ASMCs number. Rabbit tracheal ASMCs were incubated for 7 days in serum free medium before the
addition of the muscarinic agonist in the culture medium for the indicated time. A. The effect of 1-5 days of incubation with 10-5 M ACh or 3 ×
10-7 M CCh on rabbit tracheal smooth muscle cell number estimated with the MTT-Cell Titer 96® AQueous One Solution Assay (Promega) method.
B. The effect of 3-15 days of incubation with 10-5 M ACh or 3 × 10-7 M CCh on rabbit tracheal smooth muscle cell number estimated with Trypan
blue method. *P < 0.05 and **P < 0.01 compared with the respective control.
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the mitogenic effect of muscarinic agonists depends
on the ASMC phenotype. Although, in airways, mus-
carinic agonists have a proliferative effect on fibroblasts
[27,28] until now available data demonstrate that sti-
mulation of muscarinic receptors is not sufficient to
induce ASMC proliferation, but the synergetic muscar-
inic receptor stimulation with growth factors may cause
an induction of mitogenesis [29]. However, our results
demonstrate that the mitogenic effect of muscarinic ag-
onists may depend on ASMC phenotype, since it seems
reasonable that the decrease of M3 receptor expression
in cells cultured in the presence of FBS, ACh or CCh is
responsible for the weak mitogenic effect of muscarinic
agonists.
It has been reported that the stimulation of muscarinic
receptors in ASMCs activates the PI3K or MAPK path-
ways [3]. However, the PI3K pathway inhibitor LY294002
reduced [3H]thymidine incorporation induced by ACh,
while MAPK pathway inhibitor PD98059 reduced [3H]thy-
midine incorporation induced by CCh. These results sug-
gest that whereas the stimulation of muscarinic receptors
may cause the [3H]thymidine incorporation in rabbit tra-
cheal ASMCs via either PI3K or MAPK pathways, these
pathways are activated differentially by ACh and CCh.
Both ACh and CCh are agonists of all muscarinic and alsonicotinic receptors. Although the main difference between
ACh and CCh is their resistance to the cholinesterase ac-
tivity, some data suggest that acetylcholine and carbachol
interact with different muscarinic receptors [30,31]. How-
ever both LY294002 and PD98059 abolished the effect of
ACh and CCh on ASMC number suggesting that although
ACh and CCh may activate PI3K or MAPK pathways dif-
ferently, the activation of both pathways is required for
ASMC proliferation.
Conclusions
In conclusion, muscarinic receptor stimulation may shift
ASMC phenotype to “proliferative”, reduce ASMC re-
sponsiveness and have a transient mitogenic effect, via
MAPK and PI3K pathway signalling, depending on the
ASMC phenotype. These results may have clinical sig-
nificance given that in chronic inflammatory airway dis-
eases increased acetylcholine release is observed in a
periodical pattern, for example during asthma attacks
[2]. Therefore, the presence of acetylcholine in the air-
way can lead to alteration in the ASMC phenotype that
makes them more prone to be affected by growth or
inflammatory factors present in the airway in such
diseases, and lead to increased proliferation rate. Both the
phenotype shift and the increased proliferation can lead



















































Figure 9 The involvement of PI3K and MAPK signalling pathways on the muscarinic agonists induced proliferation of ASMCs. Rabbit
tracheal ASMCs were incubated for 7 days in serum free medium before the addition of either FBS (10%), ACh (10-5 M) or CCh (3 × 10-7 M) for
24 h with or without either PD98059 (100 μM) in A or LY294002 (20 μM) in B. **P < 0.01 compared with control. #P < 0.05 and ##P < 0.01
compared with the effect of control, 10% FBS or muscarinic agonist alone on cell number.
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http://www.biomedcentral.com/1471-2466/14/39characteristics of airway remodeling. Furthermore, there
are studies that propose that muscarinic agonists have an
immediate effect on airway tone, since they can increase
the contractility of isolated ovine tracheal strips [2,32-34].
This acute effect of muscarinic agonists on airways, ac-
companied by changes in ASMC phenotype and induc-
tion of cell proliferation under prolonged incubation,
indicates the significance of muscarinic agonists in the
physiology and pathophysiology of airway function.
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